These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17045397)

  • 21. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease.
    Verwey NA; van der Flier WM; Blennow K; Clark C; Sokolow S; De Deyn PP; Galasko D; Hampel H; Hartmann T; Kapaki E; Lannfelt L; Mehta PD; Parnetti L; Petzold A; Pirttila T; Saleh L; Skinningsrud A; Swieten JC; Verbeek MM; Wiltfang J; Younkin S; Scheltens P; Blankenstein MA
    Ann Clin Biochem; 2009 May; 46(Pt 3):235-40. PubMed ID: 19342441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting.
    Dumurgier J; Vercruysse O; Paquet C; Bombois S; Chaulet C; Laplanche JL; Peoc'h K; Schraen S; Pasquier F; Touchon J; Hugon J; Lehmann S; Gabelle A
    Alzheimers Dement; 2013 Jul; 9(4):406-13. PubMed ID: 23141384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
    Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.
    Blasko I; Lederer W; Oberbauer H; Walch T; Kemmler G; Hinterhuber H; Marksteiner J; Humpel C
    Dement Geriatr Cogn Disord; 2006; 21(1):9-15. PubMed ID: 16244482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.
    Lelental N; Brandner S; Kofanova O; Blennow K; Zetterberg H; Andreasson U; Engelborghs S; Mroczko B; Gabryelewicz T; Teunissen C; Mollenhauer B; Parnetti L; Chiasserini D; Molinuevo JL; Perret-Liaudet A; Verbeek MM; Andreasen N; Brosseron F; Bahl JM; Herukka SK; Hausner L; Frölich L; Labonte A; Poirier J; Miller AM; Zilka N; Kovacech B; Urbani A; Suardi S; Oliveira C; Baldeiras I; Dubois B; Rot U; Lehmann S; Skinningsrud A; Betsou F; Wiltfang J; Gkatzima O; Winblad B; Buchfelder M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2016 Mar; 52(1):51-64. PubMed ID: 26967210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe.
    Hort J; Bartos A; Pirttilä T; Scheltens P
    Eur J Neurol; 2010 Jan; 17(1):90-6. PubMed ID: 19659752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
    J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers.
    Mattsson N; Andreasson U; Carrillo MC; Persson S; Shaw LM; Zegers I; Zetterberg H; Blennow K
    Biomark Med; 2012 Aug; 6(4):401-7. PubMed ID: 22917142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF biomarker variability in the Alzheimer's Association quality control program.
    Mattsson N; Andreasson U; Persson S; Carrillo MC; Collins S; Chalbot S; Cutler N; Dufour-Rainfray D; Fagan AM; Heegaard NH; Robin Hsiung GY; Hyman B; Iqbal K; Kaeser SA; Lachno DR; Lleó A; Lewczuk P; Molinuevo JL; Parchi P; Regeniter A; Rissman RA; Rosenmann H; Sancesario G; Schröder J; Shaw LM; Teunissen CE; Trojanowski JQ; Vanderstichele H; Vandijck M; Verbeek MM; Zetterberg H; Blennow K;
    Alzheimers Dement; 2013 May; 9(3):251-61. PubMed ID: 23622690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid biomarkers for Alzheimer's disease.
    Blennow K; Zetterberg H
    J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of CSF markers in the early diagnosis of Alzheimer's disease].
    Vos SJ; Visser PJ; Verhey FR
    Tijdschr Psychiatr; 2011; 53(9):647-53. PubMed ID: 21898322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study.
    Gabelle A; Dumurgier J; Vercruysse O; Paquet C; Bombois S; Laplanche JL; Peoc'h K; Schraen S; Buée L; Pasquier F; Hugon J; Touchon J; Lehmann S
    J Alzheimers Dis; 2013; 34(1):297-305. PubMed ID: 23186986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
    Wallin AK; Blennow K; Andreasen N; Minthon L
    Dement Geriatr Cogn Disord; 2006; 21(3):131-8. PubMed ID: 16391474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease.
    Brettschneider J; Petzold A; Schottle D; Claus A; Riepe M; Tumani H
    Dement Geriatr Cogn Disord; 2006; 21(5-6):291-5. PubMed ID: 16484807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
    Formichi P; Battisti C; Radi E; Federico A
    J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurochemical dementia diagnostics: assays in CSF and blood.
    Lewczuk P; Hornegger J; Zimmermann R; Otto M; Wiltfang J; Kornhuber J
    Eur Arch Psychiatry Clin Neurosci; 2008 Nov; 258 Suppl 5():44-9. PubMed ID: 18985294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood].
    Vogelgsang J; Wiltfang J
    Nervenarzt; 2019 Sep; 90(9):907-913. PubMed ID: 31407045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.